ConvaTec Group (LON:CTEC – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Berenberg Bank in a report issued on Tuesday,Digital Look reports. They presently have a GBX 340 price objective on the stock. Berenberg Bank’s target price suggests a potential upside of 45.05% from the company’s previous close.
Other research analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 315 target price on shares of ConvaTec Group in a research report on Wednesday, April 8th. Citigroup reaffirmed an “outperform” rating and issued a GBX 315 target price on shares of ConvaTec Group in a research report on Thursday, March 5th. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 315 target price on shares of ConvaTec Group in a research report on Wednesday, March 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 325 target price on shares of ConvaTec Group in a research report on Friday, April 10th. Nine research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of GBX 319.67.
Get Our Latest Stock Analysis on ConvaTec Group
ConvaTec Group Trading Down 1.0%
Insider Buying and Selling
In other ConvaTec Group news, insider Jonny Mason sold 291,149 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of GBX 234, for a total value of £681,288.66. 0.95% of the stock is owned by company insiders.
About ConvaTec Group
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Read More
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
